RESUMO
Objectives. A variety of different anti-SARS-CoV-2 IgG antibody tests are already available in medical laboratories worldwide, and it is quite difficult to compare obtained results due to the diversity and lack of standardization. METHODS. The study included 16 serum samples of patients vaccinated against COVID-19 with different kinds of vaccines and their combinations. Two commonly used anti-SARS-CoV-2 IgG spike protein antibody quantitative assays (Abbott Chemiluminescent Microparticle Immunoassay (CMIA) and EUROIMMUN ELISA) were evaluated for correlation. RESULTS. SARS-CoV-2 IgG antibody results of Abbott CMIA and EUROIMMUN ELISA assays demonstrated a good correlation (r = 0.7902) between obtained results among patients. Only one sample showed discordant results, respectively;CMIA displayed positive (68 AU/mL;cut-off value is 50 AU/mL), but ELISA-a negative (0.7 ratio;cut-off value is 0.8 ratio) result. CONCLUSIONS. Anti-SARS-Cov-2 IgG spike protein antibody results correlate between Abbott CMIA and EUROIMMUN ELISA assay, despite the lack of standardization of these assays. However, more studies with a wider range of participants need to be carried out to fully demonstrate and prove this correlation, also considering each patient's history of vaccination against COVID-19 and possible COVID-19 infection in their medical history.
RESUMO
BACKGROUND AND AIMS: The current strategy to fight against the COVID-19 pandemic involves active patient vaccination. Patients with renal and autoimmune diseases are in high risk for severe COVID-19 infection [1]. Therefore they should be prioritized for vaccination. Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerulonephritis triggered by mucous membrane alteration;however, there is a discussion about vaccination-caused IgA flare [2]. The immunological nature of IgAN and misleading information in public sources leaves patients skeptical about whether to get vaccinated [3]. The study aimed to investigate the impact of SARS-CoV-2 vaccination on the clinical course of IgA nephropathy. METHOD: Adult patients treated in Pauls Stradins Clinical University Hospital with morphologically proven IgAN were included in the study. Patients with secondary IgAN were excluded. Evaluation of clinical and laboratory markers was performed on inclusion visit and on the second visit 6 months later. SARS-CoV-2 vaccination type and status were noted on both visits. Estimated GFR was calculated with CKD-EPI creatinine-cystatin equation. IBM SPSS Statistics version 27 and Microsoft Excel 10 were used for data analysis. RESULTS: The study involved 54 patients, 36 were unvaccinated and 18 were fully vaccinated. A significant difference between the two groups was observed by baseline proteinuria. Other differences were not observed. Fourteen patients were vaccinated with mRNA vaccine, 13 with Comirnaty and 1 with Spikevax, and four patients were vaccinated with Vaxzevria vector vaccine. The differences between the two groups are shown in Table 1. During study period, two patients had COVID-19 infection;a patient in the vaccinated group had COVID-19 prior to vaccination. CONCLUSION: SARS-CoV-2 vaccination did not affect the clinical course of IgA nephropathy. Our study results indicate that SARS-CoV-2 vaccination in IgA nephropathy patients was safe regarding renal function and disease activity markers. (Table Presented).